IMM60 and Pembrolizumab Study for Advanced Melanoma & NSCLC

Ian B. Walters, MD – Portage Biotech Inc

The IMPORT-201 study investigates the use of IMM60, a novel iNKT agonist, in combination with pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC). Preclinical studies have shown promising results, including tumor regression and immune activation. Initial results from the phase 1 portion of the study demonstrate that IMM60, as monotherapy and in combination with pembrolizumab, is well-tolerated and shows potential in inducing positive treatment responses, warranting further investigation in heavily pretreated patients.